INTRODUCTION
============

Genetic susceptibility and environmental exposures play roles in the etiology of leukemia \[[@B1]\]. Environmental exposures like ionizing radiation, benzene, and cytotoxic therapy are some of the proposed causes of acute leukemia and for genetic susceptibility, single nucleotide polymorphism (SNP) the most common type that consists of a variation at a single base pair. Depending on where it is located, SNPs can interfere with a gene's function, affecting metabolic pathways and thus affecting the course of the disease and its progress. SNPs in the xenobiotic system, cell regulation, and DNA repair system have been identified as risk factors in childhood leukemia \[[@B2], [@B3]\]. Therefore, functional polymorphisms in genes encoding carcinogen-metabolizing enzymes may have relevance in determining susceptibility to pediatric cancer \[[@B4]\].

All xenobiotics, including therapeutic agents, are metabolized and eliminated from the body by a system of enzymes encoded by specific genes. Most of these genes are polymorphic and some polymorphic forms have an altered enzyme activity \[[@B5]\]. As the cytochrome group represents the first line of defense against toxic chemicals, carcinogens and used drugs \[[@B6]\], the genetic variants in these xenobiotic metabolizing enzymes can significantly affect the susceptibility to childhood acute lymphoblastic leukemia (ALL) \[[@B7]\]. For this reason, two genes of this cytochrome family *CYP1A1* and *CYP2D6* have gained much interest and many genetic variants have been reported in both the genes.

Kashmir valley located at a high altitude in the northern part of India, have preserved genetic pool mostly due to consanguineous marriages \[[@B8]\]. Owing to this factor and its geographical location Kashmiris show wide genetic diversity from the rest of India. There is no population-based tumor registry at this moment and the various studies relating to the epidemiologic facts of cancer in Kashmir are essentially hospital based. As per the recent study conducted by Muzaffar et al., \[[@B9]\] on pattern and profile of childhood malignancies in Kashmir showed that ALL is the leading childhood malignancy which accounts for \~37% of the total childhood malignant cases and reportedly child is exposed to a range of xenobiotics through maternal and paternal lifestyle habits. But the role of polymorphisms in genes involved in such xenobiotic metabolism, the interaction among them and with the environment is not yet studied in Kashmir. Therefore we conducted a case-control study in Kashmir to assess the risk of ALL associated with polymorphisms in *CYP1A1* and *CYP2D6*.

MATERIALS AND METHODS
=====================

**Study subjects and data collection :**This study included 200 newly diagnosed histopathological confirmed childhood ALL patients and 200 controls. ALL patients were diagnosed as per French--American-British (FAB) criteria \[[@B10], [@B11]\] in the Division of Clinical Haematology of Sher-i-Kashmir Institute of Medical Sciences (SKIMS), only tertiary care hospital in the whole Kashmir Valley located in Srinagar, the central city in Kashmir valley. This study was conducted between March 2012 and December 2015. The inclusion criteria for ALL cases were (1) Complete clinical history was available; (2) Patients below the age of 20 years (3) Subjects of Kashmir origin. All the controls were recruited from SKIMS and the criteria for inclusion in the control group were: (1) Kashmiri patients enrolled for minor ailments (like a hernia, urinary stones, diarrhoea, appendicitis, prostatitis, pancreatitis, fever workup, jaundice, biliary stones, trauma/accidents, infections, and fractures). (2) Age, gender, and district matched with respective ALL cases and (3) had no history of any malignancy. The research protocol was approved by the Institutional Ethics Committee of SKIMS and informed consent was obtained from all participating individuals or parents involved in the study. Structured questionnaires were used to collect information on age, sex, place of residence, parental education, smoking; family history, monthly income and other possible confounding factors of interest in face to face interviews. No proxies were used in the study.

**Collection of blood sample and genotyping** **:**Two milliliters of venous blood was collected from each patient in EDTA coated plastic vial and stored at −80ºC before DNA extraction. Genomic DNA was extracted from blood samples by using the phenol-chloroform method \[[@B12]\]. The DNA extracted was quantified and stored at -20ºC until used for polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). The *CYP1A1*\*2A (rs4646903) and *CYP2D6*\*4 (**rs3892097**) polymorphisms were determined as described previously \[[@B13], [@B14]\].

**Statistical** **Analysis:**Categorical variables were set for presenting and calculating numbers and percentages for different variants of *CYP2D6* and *CYP1A1*. Conditional logistic regression models were used to calculate odds ratios (ORs) and corresponding 95 % confidence intervals (CIs) to assess the association of various polymorphisms of *CYP2D6*\*4 and *CYP1A1*\*2A with childhood ALL risk and to assess the possible gene--gene and gene--environment interactions. The adjustment was made for known risk factors like age, sex, residence, parental education level, monthly income, parental occupation, smoking, family history of cancer and in utero X-ray exposure during pregnancy. All statistical analysis was done using Stata software, version 12 (STATA Corp., College Station, TX, USA). Two-sided P\<0.05 was considered as statistically significant.

RESULTS
=======

Distribution of demographic factors, the wealth scores a socioeconomic indicator, paternal smoking, and allele frequency by case status are shown in [Table 1](#T1){ref-type="table"}. The majority of cases were ≤5 years of age and 60% were males. A number of ALL cases resided in rural areas than respective controls. Distribution of non-genetic factors in cases and controls including paternal smoking status around the period of conception (P=0.045), paternal occupation (P\<0.001) and in utero X-ray exposure during pregnancy (P=0.045) was significantly different among cases and controls. However, no significant differences were observed between parental education (P=0.317), monthly income (P=0.230) and family history of cancer (P=0.527) among cases and controls.

Genotypic frequencies of both *CYP1A1* and *CYP2D6* in ALL cases and controls are summarized in [Table 2](#T2){ref-type="table"}. We found that both variant (CC) and heterozygous genotype (CT) of *CYP1A1\*2A* polymorphism were associated with ALL risk, but this risk did not persist in the adjusted model (OR=6.76, P\>0.100), when results were adjusted for potential confounders. Further, the association did not persist when CC and TT genotypes were grouped together in the adjusted model (OR=1.36, P=0.002).

###### 

Demographic characters of childhood ALL cases and controls

  **Variables**                                                   **Cases n (%)**   **Controls n (%)**   **P** [a](#TFN1){ref-type="table-fn"}
  ---------------------------------------------- ---------------- ----------------- -------------------- ---------------------------------------
  **Age**                                        ≤5               110 (55.0)        110 (55.0)           1.000
                                                 6-10             60 (30.0)         60 (30.0)            
                                                 \>10             30 (15.0)         30 (15.0)            
                                                                                                         
  **Gender**                                     Male             120 (60.0)        120 (60.0)           1.000
                                                 Female           80 (40.0)         80 (40.0)            
                                                                                                         
  **Dwelling**                                   Urban            65 (32.5)         65 (32.5)            1.000
                                                 Rural            135 (67.5)        135 (67.5)           
                                                                                                         
  **Paternal occupation**                        Govt. employee   20 (10.0)         55 (27.5)            \<0.001
                                                 Business         28 (14.0)         45 (22.5)            
                                                 Farmer           66 (33.0)         54 (27.0)            
                                                 Labour           86 (43.0)         46 (23.0)            
                                                                                                         
  **Paternal smoking**                           Yes              115 (57.5)        95 (47.5)            0.045
                                                 No               85 (42.5)         105 (52.5)           
                                                                                                         
  **Monthly income**                             \<10,000         108 (54.0)        96 (48.0)            0.230
                                                 \>10000          92 (46.0)         104 (52.0)           
                                                                                                         
  **Parental education**                         Yes              95 (47.5)         105 (52.5)           0.317
                                                 No               105 (52.5)        95 (47.5)            
                                                                                                         
  **In utero X-ray exposure during pregnancy**   Yes              105 (52.5)        85 (42.5)            0.045
                                                 No               95 (47.5)         115 (57.5)           
                                                                                                         
  **Family history of cancer**                   Yes              72 (36.0)         66 (33.0)            0.527
                                                 No               128 (64.0)        134 (67.0)           

Chi- square test (χ2) was used to calculate *P*-values for categorical variables. *n*, number of individuals

###### 

Distribution of *CYP1A1\*2A and CYP2D6\*4*genotypes among cases and controls and their interaction among themselves in modulating the risk of ALL in Kashmir, India

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Variable**                                                               **Cases n (%)**   **Controls n (%)**   **Crude OR** [1](#TFN2){ref-type="table-fn"} **(95% CI)**[2](#TFN3){ref-type="table-fn"}   **Adj OR** [3](#TFN4){ref-type="table-fn"} **(95% CI)** [2](#TFN3){ref-type="table-fn"}   **P**
  -------------------------------------------------------------------------- ----------------- -------------------- ------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------- ----------
  ***CYP1A1***                                                                                                                                                                                                                                                                                           

  TT                                                                         142 (71.0)        168 (84.0)           1.0                                                                                        1.0                                                                                       \-

  CT                                                                         53 (26.5)         31 (15.5)            2.14 (1.30 -- 3.56)                                                                        1.32 (0.71 -- 2.48)                                                                       0.005

  CC                                                                         5 (2.5)           1 (0.5)              9.70 (1.07 -- 87.83)                                                                       6.76 (0.63 -- 71.88)                                                                      0.100

  CC+TC                                                                      58 (29.0)         32 (16.0)            2.18 (1.32 -- 3.61)                                                                        1.36 (0.73 -- 2.53)                                                                       0.002

  ***CYP2D6***                                                                                                                                                                                                                                                                                           

  GG                                                                         86 (43.0          190 (95.0)           1.0                                                                                        1.0                                                                                       \-

  AG                                                                         43 (21.5)         6 (3.0)              26.3 (6.54 -- 105.5)                                                                       42.67 (8.37 -- 217.5)                                                                     \<0.0001

  AA                                                                         71 (35.5)         4 (2.0)              27.43 (8.73 -- 86.14)                                                                      20.96 (6.01 -- 73.13)                                                                     \<0.0001

  AA+AG                                                                      114 (57.0)        10 (5.0)             27.0 (9.95 -- 73.24)                                                                       27.73 (9.12 -- 84.32)                                                                     \<0.0001

  ^4^ **Gen- gene interaction between** ***CYP1A1*** **and** ***CYP2D6***\                                                                                                                                                                                                                               
  **(*p*interaction = 0.487 ; SE = 0.225)**                                                                                                                                                                                                                                                              

  TT+GG                                                                      61 (30.5)         162 (81.0)           1.0                                                                                        1.0                                                                                       

  CC+TC & GG                                                                 25 (12.5)         28 (14.0)            32.68 (10.49 -- 101.8)                                                                     50.2 (12.57 -- 200.7)                                                                     

  TT & (AA+AG)                                                               81 (40.5)         6 (3.0)              2.02 (0.98 -- 4.16)                                                                        1.24 (0.48 -- 3.22)                                                                       

  CC+TC & AA+AG                                                              33 (16.5)         4 (2.0)              26.40 (6.19 -- 112.6)                                                                      8.81 (2.07 -- 37.57)                                                                      
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OR=odds ratio.

CI=confidence interval

Adjusted ORs were obtained from conditional logistic regression models when adjusted for age, family history, parental education level, paternal occupation, place of residence, socioeconomic status and paternal smoking.

High risk of ALL was found in the AA (OR=20.9, P\<0.0001) and AG genotypes of *CYP2D6\*4* (OR=42.6; P\<0.0001) and the risk was retained when (AA) and (AG) carriers were grouped together (OR=27.7, P\<0.0001). The magnitude of risk associated with AA, AG, and AG + AA was almost similar in the unadjusted model. Further, on analyzing any possible gene--gene interaction, we did not find any significant interactions between *CYP1A1* and *CYP2D6* (p interaction=0.487).

DISCUSSION
==========

The present study determined the association of *CYP1A1* and *CYP2D6* polymorphisms with ALL risk in Kashmiri population. This population has relative genetic homogeneity \[[@B8]\] which makes it an ideal genetic model for carrying out such studies. We found that unlike *CYP1A1\*2A*, *CYP2D6\*4* polymorphism is associated with ALL risk. CYP450s are heme-containing enzymes important to phase I-dependent metabolism of drugs and other xenobiotics \[[@B15]\]. Studies have persistently associated polymorphisms in these CYP genes with individual susceptibility to many cancers \[[@B16]-[@B20]\]. However, the role of such polymorphism in cancer development is not conclusive \[[@B21]\]. Despite much investigation, little is known about the mechanism of leukemogenesis. Polymorphism in *CYP2D6* gene at position G1934A causes a disruption of the splice site at the intron3/exon4 boundary that leads to incorrect splicing of mRNA resulting in a frame shift and premature termination that generates a truncated protein \[[@B22]\]. These polymorphisms usually lead to no or reduced activity of the CYP2D6 protein, resulting in the poor metabolizer phenotype \[[@B23]\]. Previous studies that have assessed the role of *CYP2D6* genetic variations in susceptibility to ALL have reported mixed results \[[@B24], [@B25]\]. In the current study, we found that *CYP2D6\*4* polymorphism is associated with ALL risk in Kashmir. A plausible explanation for our finding could be that as the *CYP2D6* gene is involved in the detoxification of carcinogenic compounds and consequently due to the absence of enzymatic activity genotoxic metabolites gets accumulated in phase I detoxification process resulting in higher risk of ALL \[[@B24]\].

*CYP1A1* gene is responsible for metabolic activation of pre-carcinogens \[[@B26]\]. Previous work revealed that the polymorphism of *Msp* I restriction site owing to a T-C variation in the 3' non-coding region of the CYP1A1 allele is experimentally associated with increased catalytic activity and increase of the amount of DNA adducts in cord blood and placenta of newborns \[[@B27]\]. In the current study, we did not find any association of *CYP1A1\*2A* with susceptibility to develop ALL. However, earlier reports have shown mixed results for this polymorphism and susceptibility to ALL. Studies have either reported the positive association of *CYP1A1\*2A* polymorphism with ALL \[[@B14], [@B25]\] or no association \[[@B28]\]. This inconsistency in the results obtained in various studies could be attributed to the variable sample size, the heterogeneity of the populations and study design. Epidemiologic studies have propounded that in utero and postnatal exposures to various biological, chemical and physical factors may be important in determining the susceptibility to childhood ALL \[[@B29]\] and as such infants and children may be at greater risk for a variety of environmental toxicants than adults due to their physiologic immaturity and/or differential exposure \[[@B27]\]. Xenobiotics enter the placenta through the maternal circulation \[[@B30]\]. Placenta has the ability to metabolize these compounds through processes similar to those seen in the liver \[[@B31]\]. Therefore, alterations in the placental metabolism could modify the exposure of the developing fetus to harmful electrophiles.

After stratification of data, we found a significant association between paternal smoking with the risk of ALL (P=0.045). Stronger evidence is accumulating now for the role of paternal smoking as reported in several individual studies and meta-analyses of ALL \[[@B32], [@B33]\]. Whilst smoking clearly impacts DNA damage which is important in carcinogenesis and therefore may influence the risk of ALL \[[@B34]\]. Paternal exposure is of concern, due to possible germline effects for fathers and passive exposure of pregnant women due to cross placental transfer from mother to baby. In utero exposure to low-dose radiation delivered from medical X-rays is one of the few widely recognized risk factors for childhood leukemia \[[@B35]\] and hence the early life exposures to these radiations have been implicated in the etiology of childhood ALL \[[@B36]\]. The increased risk of ALL conferred by in utero X-ray exposure found in this study is in agreement with the recent study \[[@B37]\]. However, other reports did not support these results \[[@B38]\]. To our knowledge, this is the first investigation that attempted to study the impact of polymorphisms of *CYP1A1* and *CYP2D6* on the risk of childhood ALL in Kashmir valley. Besides this study assessed the role of certain non-genetic factors in the development of ALL as well. However further studies with larger sample size are warranted to replicate the findings.
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